Property:Outcome specification
This is a property of type Text.
J
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Loco-regional recurrences in % +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Incidence of second primary tumors +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Serum vitamin A level +
K
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
NA +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
5-year OS +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
NA +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
DFS Randomization until secondary tumors or recurrence and 5-year DFS +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
'''Tension'''
Assessed by the investigator with a four point rating scale:
0 = no tension
1 = slight tension
2 = moderate tension
3 = severe tension +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
'''Skinfold thickness'''
(Parameter of fibrosis) was measured with a calliper in mm and devided by 2 for the normal measurement of the skinfold in not fibrotically changed skin. Measures of the absolute values were taken from the upper arm, the lower arm, the hand and from the third finger. The absolute reference value is 2 mms for the healthy skin. +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
'''Volume reduction'''
measured by Volometer = opto-electronic device measures the arm circumference 2-dimensionally along a distance of 45cm on the entire arm according to the kuhnke formula. As reference the healthy arm of each individual is measured. +
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer +
Vaginal atrophy, pH, and vaginal maturation index +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Specifically tumor clearance, i.e. the proportion of patients with complete histological tumor clearance after eight weeks (time point 3) +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Specifically tumor size,
examination after three weeks (time point 1), six weeks (time point 2) and eight weeks (time point 3) +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
Evidenced by any of the following three events: an increase in the HAQ-II score of 0.25 or more; an increase in CPIS score; or discontinuation of letrozole specifically due to aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +